Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today announces that an abstract with clinical data from the ATLAS-IT-05 study is accepted for presentation at ESMO 2023.
In ATLAS-IT-05, a Phase II study, LTX-315 is given to patients with advanced melanoma in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda), a market leading approved immunotherapeutic antibody. In the abstract interim efficacy and safety data from the first patients enrolled in the Phase II study are presented.
The interim data will be presented by the leading investigator of the trial, Professor Stéphane Dalle (Centre Hospitalier Universitaire de Lyon, France) in a poster session. The poster title is: Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: interim results from the ATLAS-IT-05 trial.
Øystein Rekdal, CEO of Lytix commented: “We are looking forward to sharing interim data from the ongoing ATLAS-IT-05 trial at this year’s ESMO in Madrid. The study is running at several sites in the US and Europe exploring the ability of LTX-315 to alter the course of disease in patients who have previously failed treatment with anti-PD-1/PDL-1.”
For more information about ATLAS-IT-05: https://clinicaltrials.gov/study/NCT04796194
